Lessons from acute HIV infection

Current Opinion in HIV and AIDS

Volumn 11, Issue 6, 2016, Pages 555-560

  Robb, Merlin L ^a,b   Ananworanich, Jintanat ^a,b  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

Author keywords

Acute HIV infection; Early antiretroviral therapy; HIV reservoir; HIV vaccine; Preventive HIV vaccine; Therapeutic HIV vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; ANTIRETROVIRUS AGENT;

CD8+ T LYMPHOCYTE; CLADISTICS; CLINICAL TRIAL (TOPIC); HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; REVIEW; VIREMIA; VIRUS TRANSMISSION; DISEASE TRANSMISSION; HIV INFECTIONS; IMMUNOLOGY; PREVENTION AND CONTROL; VIROLOGY; VIRUS LOAD;

AIDS VACCINES; ANTI-RETROVIRAL AGENTS; CD8-POSITIVE T-LYMPHOCYTES; DISEASE TRANSMISSION, INFECTIOUS; HIV INFECTIONS; HUMANS; VIRAL LOAD;

EID: 84991662084     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000316     Document Type: Review

References (43)

1. Robb ML, Eller LA, Kibuuka H, et al. Prospective study of acute HIV-1 infection in adults in east Africa and Thailand. N Engl J Med 2016; 374:2120-2130.
2. Schuetz A, Deleage C, Sereti I, et al. Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation. PLoS Pathog 2014; 10:e1004543.
3. Deeks SG, Lewin SR, Ross AL, et al. International AIDS Society global scientific strategy: towards an HIV cure. Nat Med 2016; 22:839-850.
4. Kelley CF, Barbour JD, Hecht FM. The relation between symptoms, viral load, and viral load set point in primary HIV infection. J Acquir Immune Defic Syndr 2007; 45:445-448.
5. Lavreys L, Baeten JM, Chohan V, et al. Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis 2006; 42:1333-1339.
6. Lefrere JJ, Roudot-Thoraval F, Mariotti M, et al. The risk of disease progression is determined during the first year of human immunodeficiency virus type 1 infection. J Infect Dis 1998; 177:1541-1548.
7. Lindback S, Karlsson AC, Mittler J, et al. Viral dynamics in primary HIV-1 infection. Karolinska Institutet Primary HIV Infection Study Group. AIDS 2000; 14:2283-2291.
8. Ananworanich J, Fletcher JL, Pinyakorn S, et al. A novel acute HIV infection staging system based on 4th generation immunoassay. Retrovirology 2013; 10:56.
9. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17:1871-1879.
10. McMichael AJ, Borrow P, Tomaras GD, et al. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2010; 10:11-23.
11. Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 Infection. N Engl J Med 2011; 364:1943-1954.
12. Ndhlovu ZM, Kamya P, Mewalal N, et al. Magnitude and kinetics of CD8(+) T cell activation during hyperacute HIV infection impact viral set point. Immunity 2015; 43:591-604.
13. Sullivan PS, Fideli U, Wall KM, et al. Prevalence of seroconversion symptoms and relationship to set-point viral load: findings from a subtype C epidemic. AIDS 2012; 26:175-184.
14. Baalwa J, Wang S, Parrish NF, et al. Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. Virology 2013; 436:33-48.
15. Parrish NF, Gao F, Li H, et al. Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci U S A 2013; 110:6626-6633.
16. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 2008; 105:7552-7557.
17. Fenton-May AE, Dibben O, Emmerich T, et al. Relative resistance of HIV-1 founder viruses to control by interferon-alpha. Retrovirology 2013; 10:146.
18. Kijak GH, Sanders-Buell E, Chenine AL, et al. Cryptic multiple HIV-1 infection revealed by early, frequent, and deep sampling during acute infection. AIDS Res Hum Retroviruses 2014; 30 (S1):A58-A60.
19. Li H, Bar KJ, Wang S, et al. High multiplicity infection by HIV-1 in men who have sex with men. PLoS Pathog 2010; 6:e1000890.
20. Tully DC, Ogilvie CB, Batorsky RE, et al. Differences in the selection bottleneck between modes of sexual transmission influence the genetic composition of the HIV-1 founder virus. PLoS Pathog 2016; 12:e1005619.
21. Carlson JM, Schaefer M, Monaco DC, et al. HIV transmission. Selection bias at the heterosexual HIV-1 transmission bottleneck. Science 2014; 345:1254031.
22. Claiborne DT, Prince JL, Scully E, et al. Replicative fitness of transmitted HIV-1 drives acute immune activation, proviral load in memory CD4+ T cells, and disease progression. Proc Natl Acad Sci U S A 2015; 112:E1480-E1489.
23. Chun TW, Engel D, Berrey MM, et al. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A 1998; 95:8869-8873.
24. Ananworanich J, editor HIV DNA Set Point Remains Elevated in Untreated vs. Treated Acutely Infected Thais 23rd Conference on Retroviruses and Opportunistic Infections; 2016 February 22-25, 2016; Boston, Massachusetts.
25. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15:893-900.
26. Group ISS, Lundgren JD, Babiker AG, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015; 373:795-807.
27. Ananworanich J, Schuetz A, Vandergeeten C, et al. Impact of multitargeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One 2012; 7:e33948.
28. Li JZ, Etemad B, Ahmed H, et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS 2016; 30:343-353.
29. Williams JP, Hurst J, Stohr W, et al. HIV-1 DNA predicts disease progression and posttreatment virological control. eLife 2014; 3:e03821.
30. Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Posttreatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013; 9:e1003211.
31. Persaud D, Luzuriaga K. Absence of HIV-1 after treatment cessation in an infant. N Engl J Med 2014; 370:678.
32. Thornhill J, Inshaw J, Kaleebu P, et al. Brief Report. Enhanced normalisation of CD4/CD8 ratio with earlier antiretroviral therapy at primary HIV infection. J Acquir Immune Defic Syndr 2016; 73:69-73.
33. Du VY, Bansal A, Carlson J, et al. HIV-1-specific CD8 T cells exhibit limited cross-reactivity during acute infection. J Immunol 2016; 196:3276-3286.
34. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 2009; 206:1253-1272.
35. De Souza MS, Phanuphak N, Pinyakorn S, et al. Impact of nucleic acid testing relative to antigen/antibody combination immunoassay on the detection of acute HIV infection. AIDS 2015; 29:793-800.
36. Lecuroux C, Girault I, Urrutia A, et al. Identification of a particular HIV-specific CD8+ T-cell subset with a CD27+ CD45RO-/RA+ phenotype and memory characteristics after initiation of HAART during acute primary HIV infection. Blood 2009; 113:3209-3217.
37. Takata H, Kessing C, Muir R, Colby D, Phanuphak N, Haddad EK, et al., editors. Differentiation of Effector CD8 T Cells Toward Short Lived Cells Lacking Memory Potential During Acute HIV Infection. Keystone Symposia; 2016 March 20-24, 2016; Olympic Valley, CA.
38. Jensen SS, Fomsgaard A, Larsen TK, et al. Initiation of antiretroviral therapy (ART) at different stages of HIV-1 disease is not associated with the proportion of exhausted CD8+ T cells. PLoS One 2015; 10:e0139573.
39. Hansen SG, Piatak M Jr, Ventura AB, et al. Immune clearance of highly pathogenic SIV infection. Nature 2013; 502:100-104.
40. Graziani GM, Angel JB. HIV-1 immunogen: an overview of almost 30 years of clinical testing of a candidate therapeutic vaccine. Expert Opin Biol Ther 2016; 16:953-966.
41. Carcelain G, Autran B. Immune interventions in HIV infection. Immunol Rev 2013; 254:355-371.
42. Suthar AB, Granich RM, Kato M, et al. Programmatic implications of acute and early HIV infection. J Infect Dis 2015; 212:1351-1360.
43. Smith MK, Rutstein SE, Powers KA, et al. The detection and management of early HIV infection: a clinical and public health emergency. J Acquir Immune Defic Syndr 2013; 63 (Suppl 2):S187-S199.